VAP expanded cholesterol test can help clinicians identify best treatment
options for patients at risk of heart disease
BIRMINGHAM, Ala., May 8 /PRNewswire/ -- Atherotech, Inc., a cardio-diagnostic company, today announced it will be exhibiting its VAP Cholesterol Test in booth No. 2123 at the American College of Physicians (ACP) Internal Medicine 2008, the premier scientific meeting for internal medicine. The annual meeting takes place May 13-17, 2008, at the Washington Convention Center in Washington, D.C.
People with a family history or an existing condition of diabetes, high blood pressure or heart disease -- or who are already taking cholesterol lowering medication -- are candidates for the comprehensive VAP (Vertical Auto Profile) Test. In addition, those who didn't score within the desirable ranges of the standard cholesterol test (i.e. those with Triglycerides > 150, HDL < 40, LDL >130, Total Cholesterol > 200) should also opt for the more detailed VAP Test.
The VAP(R) Cholesterol Test (Atherotech, Inc.) is the only commercially available advanced lipid profile that routinely reports all three lipoprotein parameters considered necessary by the recent expert consensus guidelines from the American Diabetes Association and American College of Cardiology.
Atherotech representatives will be available to discuss the VAP expanded cholesterol test in booth No. 2123, and blood draws will be provided to qualified attendees. Test results will be returned via mail after the conference.
The VAP Test is the most accurate and comprehensive cholesterol test
available today, measuring 15 separate components of blood cholesterol as
opposed to three in a standard test. The comprehensive test can identify
more than twice the number of lipid abnormalities (the No. 1 risk factor of
heart disease) than the standard cholesterol test, and is the only
cholesterol test to identify markers for Metabolic Syndrome, a precursor
|SOURCE Atherotech, Inc.|
Copyright©2008 PR Newswire.
All rights reserved